Valuation: Insmed Incorporated

Market Cap 21.34B 18.53B 17.28B 15.87B 30.01B 2,030B 30.34B 204B 79.62B 1,015B 80.14B 78.38B 3,362B P/E 2026 *
-38x
P/E 2027 * 196x
Enterprise Value 20.78B 18.04B 16.82B 15.45B 29.22B 1,976B 29.54B 198B 77.52B 988B 78.02B 76.31B 3,273B EV / Sales 2026 *
12.2x
EV / Sales 2027 * 7.34x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day+0.45%
1 week-5.13%
Current month+0.19%
1 month-11.43%
3 months-29.44%
6 months-35.19%
Current year-43.24%
1 week 96.42
Extreme 96.42
106.26
1 month 96.42
Extreme 96.42
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%-5.13%-11.19%+349.25% 21.34B
+10.00%+13.39%+51.99%+83.45% 56.7B
+0.80%-7.82%+24.61%+60.00% 51.97B
-0.88%-1.00%-16.81%-14.04% 23.33B
+1.73%-1.57%+32.81%-25.80% 17.44B
+4.29%+1.67%+201.24%+344.48% 14.77B
+1.49%-0.67%+52.49%+176.91% 13.84B
+4.22%+3.74%+440.45%+181.15% 12.12B
+5.40%-5.15%+63.73%+162.76% 11.14B
+2.95%-0.76%+115.55%+137.57% 10.38B
Average +3.04%-1.08%+95.49%+145.57% 23.3B
Weighted average by Cap. +3.67%+0.19%+64.86%+118.00%

Financials

2026 *2027 *
Net sales 1.7B 1.48B 1.38B 1.27B 2.4B 162B 2.42B 16.26B 6.36B 81.01B 6.4B 6.26B 268B 2.78B 2.41B 2.25B 2.06B 3.9B 264B 3.95B 26.49B 10.36B 132B 10.42B 10.19B 437B
Net income -559M -485M -452M -416M -786M -53.15B -795M -5.33B -2.08B -26.57B -2.1B -2.05B -88.04B 70.55M 61.26M 57.12M 52.47M 99.24M 6.71B 100M 673M 263M 3.35B 265M 259M 11.12B
Net Debt -563M -489M -456M -419M -792M -53.56B -801M -5.37B -2.1B -26.77B -2.11B -2.07B -88.71B -979M -850M -792M -728M -1.38B -93.08B -1.39B -9.34B -3.65B -46.53B -3.67B -3.59B -154B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-04 US$98.83 +0.38% 3,155,382
26-08-03 US$98.45 -0.15% 3,546,860
26-07-31 US$98.60 -2.85% 2,902,595
26-07-30 US$101.49 -1.58% 3,363,495
26-07-29 US$103.12 -0.97% 2,195,533
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
98.45USD
Average target price
195.95USD
Spread / Average Target
+99.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock